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Increased vancomycin minimum inhibitory concentration among Staphylococcus aureus isolates in Malaysia
Vancomycin is one of the very few antibiotics available for the treatment of meticillin-resistant Staphylococcus aureus (MRSA). A shift towards higher vancomycin MIC values has been observed among meticillin-susceptible and -resistant S. aureus strains (Wang et al., 2006; Steinkraus et al., 2007) . This increase in MICs over time, referred to as 'MIC creep', is usually not recognized because these small increases are still within susceptible limits unless analyses are carried out to see the increasing trend over the years. However, even small increases in MIC below the susceptibility breakpoint can affect the clinical efficacy (Sakoulas et al., 2004; Moise & Schentag, 2000) .
In Malaysia, 26 % of S. aureus isolates from clinical specimens in 2008 were MRSA. Out of 2389 cases of bacteraemia due to S. aureus in 2008, 21 % were caused by MRSA. S. aureus is also the second most common bacterium isolated from blood (Ministry of Health, 2008) . Heterogeneous vancomycin-sensitive S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus have not been documented in Malaysia; however, vancomycin treatment failure in vancomycin-susceptible MRSA has been reported and its occurrence may not be uncommon (Norazah et al., 2009 (Walsh et al., 2001) . Hsu et al. (2008) showed that Etest MIC results appear to be more precise and predictive of treatment response than results obtained by the standard twofold dilution method.
Increasing vancomycin MIC within the susceptible range was associated with a significant risk for vancomycin treatment failure in MRSA bacteraemia (Sakoulas et al., 2004) . Higher clinical failure in MRSA bacteraemia was noted with vancomycin MIC ¢1.5 mg ml 21 (Lodise et al., 2008; Soriano et al., 2008) . A higher failure rate was associated with strains with vancomycin MIC of ¢1.5 mg ml 21 compared to those with MICs ¡1 mg ml
21
by Etest (Lodise et al., 2008) . MRSA isolates that show reduced susceptibility to vancomycin (with an MIC at the breakpoint for susceptibility) are highly prevalent among strains that cause invasive infections (Hidayat et al., 2006) . In our study, a greater proportion of isolates with vancomycin MIC 2 mg ml 21 than of low-MIC strains were involved in bloodstream infections. Even though in this study we did not correlate the clinical outcome of MRSA bacteraemia, the possibility of vancomycin treatment failures in our hospital settings could not be ruled out and is an area of concern. The presence of subpopulations of resistant strains is also a possible cause for vancomycin treatment failure for the seemingly susceptible MRSA strains. These strains are difficult to detect and appear fully susceptible when tested by the BMD method or Etest. Vancomycin has been the main antibiotic used for the treatment of serious MRSA infections, while b-lactam antibiotics still remain the treatment of choice for MSSA infections. Prior recent exposure to vancomycin has been associated with reduced susceptibility of MRSA bloodstream isolates and increased tolerance to vancomycin in vitro (Moise et al., 2008) . In vitro evaluations have demonstrated a relationship between exposure to low vancomycin serum concentrations and the development of heteroresistant vancomycin-intermediate S. aureus (Liu & Chambers, 2003 (Wang et al., 2006; Steinkraus et al., 2007; Robert et al., 2006; Ho et al., 2010) .
Isolates with vancomycin MICs of ¢1 mg ml 21 tend to be less susceptible to other antimicrobial agents (Wang et al., 2006) . 
